Recursion Pharmaceuticals (RXRX) is up 17.9%, or 93c to $6.17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Unusually active option classes on open September 25th
- Strategic Growth and Unique Positioning Drive Buy Rating for Recursion Pharmaceuticals
- Recursion Pharmaceuticals management to meet with Needham
- Buy Recommendation for Recursion Pharmaceuticals: Strong Position in AI-Driven Drug Discovery with Strategic Acquisitions and Financial Stability
- Private Markets: Anthropic raises $13B Series F at $183B post-money valuation